Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Takeda
Biotech
Takeda narcolepsy blockbuster hopeful secures double ph. 3 wins
Takeda is on track to submit its narcolepsy drug to regulators this fiscal year after the OX2R-selective agonist scored a pair of phase 3 wins.
James Waldron
Jul 14, 2025 5:51am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
Keros culls phase 2 PAH program, 70 staff roles
May 29, 2025 10:10am
Takeda shoots down bispecifics bagged in Maverick buyout
May 8, 2025 8:30am
Keros mulls sale, strengthens defense against activist investors
Apr 10, 2025 8:44am
Arch-backed tRNA biotech shutters after viewing preclinical data
Mar 18, 2025 10:15am
